Spectral Diagnostics Inc.

  • Toronto, Ontario
- www.spectraldx.com/
  • Biotechnology
  • Computers
  • Healthcare Facility
  • Medical/ Pharmaceuticals

Organization Profile

Spectral is a Phase III company seeking U.S. FDA approval for its lead theranostics product for the treatment of patients with septic shock. Toraymyxin is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis, Spectral's EUPHRATES trial is the world's first theranostics trial in the area of sepsis

Contact Information

Anthony Businskas
Executive Vice President and CFO
Tel: 416-626-3233

Adam Peeler
Investor Relations
Tel: 416-815-0700 x225
Fax: 416-815-0080

Market Performance